Company intelligence / Profile preview

Lassen Therapeutics 1 PTY LTD

Ownership: Private
Employees: ~25
Development stage: Phase 1

Overview

LASN01, a fully human monoclonal antibody against interleukin-11 receptor, completed Phase 1/2 trials in thyroid eye disease and idiopathic pulmonary fibrosis; Phase 2 studies ongoing in thyroid eye disease. Preclinical and clinical data show potent blockade of IL-11 signaling leading to reduction in fibrosis and inflammation, with initial safety and tolerability demonstrated.

Therapeutic areas: OncologyEndocrinologyPulmonology
Modalities: Monoclonal antibody
Industry: Biotech

Drug pipeline

2 assets

LASN01

Phase 1

Indications: Thyroid Eye Disease, Idiopathic Pulmonary Fibrosis

1 more asset in the full pipeline.

Request access →

Partnerships

Cedars Sinai Medical Center (collaboration for fibrosis research)Olivia Newton-John Cancer Research Institute (oncology preclinical collaboration)

Beyond the preview

Go deeper on Lassen Therapeutics 1 PTY LTD.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lassen Therapeutics 1 PTY LTD.

Explore the full profile